摘要
目的 探讨沙美特罗替卡松粉吸入剂(商品名:舒利迭)结合布地奈德治疗妊娠期哮喘的疗效及对唾液中分泌型免疫球蛋白A(SIgA)、皮质醇(Cor)水平的影响。方法 112例妊娠期哮喘孕妇,以随机数字表法分为对照组和研究组,每组56例。对照组应用布地奈德治疗,研究组应用舒利迭结合布地奈德治疗。比较两组临床疗效,喘息消失时间、哮鸣音消失时间及住院时间,治疗前后肺功能指标[第1秒用力呼气容积占预计值的百分比(FEV1%pred)、呼气峰值流速占预计值的百分比(PEF%pred)及第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)]及唾液中SIgA、Cor水平,不良反应发生情况。结果 研究组总有效率为96.43%,高于对照组的82.14%,差异具有统计学意义(P<0.05)。研究组喘息消失时间、哮鸣音消失时间及住院时间分别为(3.11±1.05)、(4.35±1.14)、(7.22±1.58)d,均短于对照组的(4.87±1.47)、(6.84±1.24)、(9.87±1.42)d,差异具有统计学意义(P<0.05)。治疗后,两组FEV1%pred、PEF%pred及FEV1/FVC均高于本组治疗前,且研究组FEV1%pred(88.95±6.57)%、PEF%pred(84.59±3.76)%、 FEV1/FVC(78.96±6.12)%显著高于对照组的(72.54±5.23)%、(72.01±3.75)%、(63.48±5.49)%,差异具有统计学意义(P<0.05)。治疗后,两组唾液中SIgA、Cor水平均高于本组治疗前,且研究组唾液中SIgA(20.44±4.21)g/L、Cor(9.53±1.47)μg/L高于对照组的(13.15±3.39)g/L、(6.56±1.38)μg/L,差异具有统计学意义(P<0.05)。研究组不良反应发生率为3.57%,低于对照组的21.43%,差异具有统计学意义(P<0.05)。结论 应用舒利迭结合布地奈德治疗妊娠期哮喘孕妇疗效显著,可大大缩短孕妇喘息及哮鸣音消失时间,有效改善肺功能,同时提高其唾液中SIgA、Cor水平,不良反应少,安全性较高,值得临床深入推广。
Objective To discuss the efficacy of salmeterol xinafoate and fluticasone propionate powder for inhalation(trade name:Seretide)combined with budesonide in the treatment of asthma in pregnancy and its influence on levels of secretory immunogloblin A(SIgA)and cortisol(Cor)in saliva.Methods A total of 112 pregnant women with asthma were divided into control group and study group according to the random numerical table,with 56 cases in each group.The control group was treated with budesonide,and the study group was treated with Seretide and budesonide.Both groups were compared in terms of clinical effect,disappearance time of wheezing,disappearance time of wheezing sound,length of hospital stay,lung function indicators[percentage of forced expiratory volume in one second to the predicted value(FEV1%pred),percentage of peak expiratory flow rate to the predicted value(PEF%pred)and ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC)],and levels of SIgA and Cor in saliva before and after treatment,and incidence of adverse reactions.Results The total effective rate of the study group was 96.43%,which was higher than that of 82.14%of the control group,and the difference was statistically significant(P<0.05).The disappearance time of wheezing,disappearance time of wheezing sound and length of hospital stay in the study group were(3.11±1.05),(4.35±1.14)and(7.22±1.58)d,which were shorter than those of(4.87±1.47),(6.84±1.24)and(9.87±1.42)d in the control group,and the differences were statistically significant(P<0.05).After treatment,FEV1%pred,PEF%pred and FEV1/FVC in both groups were higher than those before treatment in this group;the study group had FEV1%pred of(88.95±6.57)%,PEF%pred of(84.59±3.76)%and FEV1/FVC of(78.96±6.12)%,which were significantly higher than those of(72.54±5.23)%,(72.01±3.75)%and(63.48±5.49)%in the control group;the differences were statistically significant(P<0.05).After treatment,the levels of SIgA and Cor in saliva in both groups were higher than those befo
作者
熊亮
成爱玲
XIONG Liang;CHENG Ai-ling(Jinan Hospital,Jinan 250014,China)
出处
《中国实用医药》
2023年第17期22-26,共5页
China Practical Medicine
关键词
沙美特罗替卡松粉吸入剂
布地奈德
妊娠期哮喘
分泌型免疫球蛋白A
皮质醇
Salmeterol xinafoate and fluticasone propionate powder for inhalation
Budesonide
Asthma in pregnancy
Secretory immunoglobulin A
Cortisol
